SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 525-538

  Puhr, Martin ^a   Santer, Frédéric R ^a   Neuwirt, Hannes ^a   Marcias, Gemma ^a   Hobisch, Alfred ^b   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b General Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; FLAVONOIDS; HUMANS; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 77953565270     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0007     Document Type: Article

References (59)

1. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M & Spencer DM 2007 Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12 559-571.
2. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spittler J & Rowley DR 2003 Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clinical Cancer Research 9 4792-4801. (Pubitemid 37323282)
3. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A et al. 2006 Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. American Journal of Pathology 169 2199-2208.
4. Ben-Zvi T, Yayon A, Gertler A & Monsonego-Ornan E 2006 Suppressors of cytokine signaling (SOCS)1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. Journal of Cell Science 119 380-387.
5. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
6. Bugler B, Amalric F & Prats H 1991 Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Molecular and Cellular Biology 11 573-577. (Pubitemid 21895236)
7. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK & Lin J 2001 Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20 7925-7934.
8. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA et al. 2007 The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26 2822-2832.
9. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C et al. 1997 Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31 223-233.
10. DeMarzo AM, Nelson WG, Isaacs WB & Epstein JI 2003 Pathological and molecular aspects of prostate cancer. Lancet 361 955-964.
11. Deo DD, Axelrad TW, Robert EG, Marcheselli V, Bazan NG & Hunt JD 2002 Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. Journal of Biological Chemistry 277 21237-21245.
12. Dey BR, Furlanetto RW & Nissley P 2000 Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochemical and Biophysical Research Communications 278 38-43.
13. Dorkin TJ, Robinson MC, Marsh C, Neal DE & Leung HY 1999 aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. Journal of Pathology 189 564-569.
14. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR & Egwuagu CE 2007 Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 26 1941-1948.
15. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM & Spencer DM 2003 Conditional activation of fibroblast growth factor receptor (FGFR)1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Research 63 6237-6243.
16. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr & Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Research 59 279-284. (Pubitemid 29048852)
17. Giri D, Ropiquet F & Ittmann M 1999 Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clinical Cancer Research 5 1063-1071. (Pubitemid 29233220)
18. Giri D, Ozen M & Ittmann M 2001 Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 159 2159-2165. (Pubitemid 33104270)
19. Hadari YR, Gotoh N, Kouhara H, Lax I & Schlessinger J 2001 Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. PNAS 98 8578-8583.
20. Hammacher A, Thompson EW & Williams ED 2005 Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. International Journal of Biochemistry & Cell Biology 37 442-450.
21. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA & Donoghue DJ 2000 Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19 3309-3320.
22. Hart KC, Robertson SC & Donoghue DJ 2001 Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Molecular Biology of the Cell 12 931-942.
23. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J & Papadimitriou E 2006 Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. Journal of Biological Chemistry 281 32217-32226.
24. Hernandez S, de Muga S, Agell L, Juanpare N, Esgueva R, Lorente JA, Mojal S, Serrano S & Lloreta J 2009 FGFR3 mutations in prostate cancer: association with low-grade tumors. Modern Pathology 22 848-856.
25. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H & Culig Z 2001 Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clinical Cancer Research 7 2941-2948. (Pubitemid 32911405)
26. Hodge DR, Hurt EM & Farrar WL 2005 The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer 41 2502-2512.
27. Ishikawa H, Tsuyama N, Liu S, Abroun S, Li FJ, Otsuyama K, Zheng X, Ma Z, Maki Y, Iqbal MS et al. 2005 Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 24 6328-6332.
28. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW & Nakayama KI 2004 VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes and Development 18 3055-3065.
29. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J & Rossi JF 2003 Survival and proliferation factors of normal and malignant plasma cells. International Journal of Hematology 78 106-113. (Pubitemid 37021949)
30. Komyod W, Bohm M, Metze D, Heinrich PC & Behrmann I 2007 Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Molecular Cancer Research 5 271-281.
31. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G & Ittmann M 2004 The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research 64 4728-4735.
32. Leung HY, Dickson C, Robson CN & Neal DE 1996 Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 12 1833-1835. (Pubitemid 26146309)
33. Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W, Dionne CA, Jaye M, RubinsteinM& Schlessinger J 1991 A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Molecular and Cellular Biology 11 5068-5078.
34. Muddasani P, Norman JC, Ellman M & van Wijnen AJ 2007 Basic fibroblast growth factor activates the MAPK and NFkappa B pathways that converge on Elk-1 to control production of matrix metalloproteinase-13 by human adult articular chondrocytes. Journal of Biological Chemistry 282 31409-31421. (Pubitemid 350044895)
35. Nakamoto T, Chang CS, Li AK & Chodak GW 1992 Basic fibroblast growth factor in human prostate cancer cells. Cancer Research 52 571-577.
36. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A & Culig Z 2007 Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocrine-Related Cancer 14 1007-1019.
37. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD et al. 2000 Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. PNAS 97 6493-6498.
38. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao C & GoldfarbM1996 Receptor specificity of the fibroblast growth factor family. Journal of Biological Chemistry 271 15292-15297.
39. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C & Ittmann M 2003 Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Research 63 5754-5760.
40. Powers CJ, McLeskey SW & Wellstein A 2000 Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer 7 165-197.
41. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L & Culig Z 2009 Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Research 69 7375-7384.
42. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F & Klocker H 1999 Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Research 59 227-233.
43. Ropiquet F, Giri D, Lamb DJ & Ittmann M 1999 FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. Journal of Urology 162 595-599.
44. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A & Ittmann M 2000 Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Research 60 4245-4250. (Pubitemid 30636612)
45. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ & Visakorpi T 2002 Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. American Journal of Pathology 160 339-345. (Pubitemid 34052294)
46. Spangenburg EE 2005 SOCS-3 induces myoblast differentiation. Journal of Biological Chemistry 280 10749-10758.
47. Spiotto MT & Chung TD 2000 STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42 88-98.
48. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A & Culig Z 2003 Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. American Journal of Pathology 162 655-663.
49. Takeuchi R, Matsumoto H, Okada H, Hori M, Gunji A, Hakozaki K, Akimoto Y & Fujii A 2007 Differences of cell growth and cell cycle regulators induced by basic fibroblast growth factor between nifedipine responders and non-responders. Journal of Pharmacological Sciences 103 168-174.
50. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD & Rowley DR 2002 Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clinical Cancer Research 8 2912-2923.
51. Udayakumar TS, Stratton MS, Nagle RB & Bowden GT 2002 Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Neoplasia 4 60-67.
52. Wang J, Stockton DW & Ittmann M 2004 The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clinical Cancer Research 10 6169-6178.
53. Wang J, Thompson B, Ren C, Ittmann M & Kwabi-Addo B 2006 Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 66 613-624.
54. Wesley UV, McGroarty M & Homoyouni A 2005 Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Research 65 1325-1334.
55. Wong CP, Bray TM & Ho E 2008 Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Letters 27 38-46.
56. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, Platt A, Gilmer TM, Fu XY & Chin YE 2002 Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. Journal of Biological Chemistry 277 30716-30723.
57. Yadav A, Kalita A, Dhillon S & Banerjee K 2005 JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. Journal of Biological Chemistry 280 31830-31840.
58. Yang F, Strand DW & Rowley DR 2008 Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 27 450-459.
59. Yasumoto H, Matsubara A, Mutaguchi K, Usui T & McKeehan WL 2004 Restoration of fibroblast growth factor receptor 2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 61 236-242.